Select a Cancer Type:
Myeloma
Myeloma
RELATED ARTICLES
%201.png?fit=crop&auto=format)
Why a Two-Drug Combination Could Change Myeloma Treatment
August 04, 2026
Learn how Talvey plus Tecvayli cut the risk of myeloma progression or death by 89%, how the combination is given and what it may mean for daily life.
.png?fit=crop&auto=format)
Dr. Ajay Nooka Explains What the MonumenTAL-6 Trial Means for Patients
July 31, 2026
Dr. Ajay Nooka discusses the MonumenTAL-6 trial and explains what the promising Tecvayli plus Talvey results could mean for patients with relapsed multiple myeloma.
Tecvayli-Talvey Combo Cuts Myeloma Progression Risk by 89%
July 24, 2026
Tecvayli plus Talvey cut the risk of disease progression or death by 89% in patients with relapsed multiple myeloma, according to new trial results.
FDA Approves Sarclisa Escena as a New Under the Skin Treatment Option for Multiple Myeloma
July 10, 2026
The FDA approved Sarclisa Escena, a new subcutaneous treatment option for adults with multiple myeloma across newly diagnosed and relapsed settings.
Tecvayli Boosts Survival in Relapsed Multiple Myeloma: MajesTEC-9 Trial
May 30, 2026
ASCO 2026: MajesTEC-9 trial shows Tecvayli cuts death risk by 40% and improves outcomes in relapsed/refractory multiple myeloma patients.
.png?fit=crop&auto=format)
Study Identifies Why Multiple Myeloma May Return After Immunotherapy
April 17, 2026
Study finds how multiple myeloma cells adapt to immunotherapy, helping explain why patients relapse and guiding personalized treatment approaches.
Advertisement
Advertisement